Bacterial proteins and enzymes

Bacterial proteins and enzymes encompass a vast array of molecular targets essential for the survival, growth, and pathogenicity of bacteria (Patsnap, 2024). These targets include enzymes involved in cell wall synthesis, such as penicillin-binding proteins (PBPs), nucleic acid replication enzymes like DNA gyrase and topoisomerase IV, and the bacterial ribosome (Guide to Pharmacology, 2024; NIH, 2022). Because many of these proteins have no direct human homologs or possess significant structural differences from their eukaryotic counterparts, they serve as the foundation for selective toxicity in antibiotic development (NIH, 2010). Targeting these molecules allows for the treatment of diverse infectious diseases ranging from minor skin infections to life-threatening sepsis (Wikipedia, 2024). However, the rapid evolution of bacterial species has led to widespread antimicrobial resistance (AMR), often through mutations in these target proteins or the acquisition of enzymes that degrade the drugs, such as beta-lactamases (Frontiers in Microbiology, 2023; NIH, 2018). Modern drug discovery continues to focus on identifying novel bacterial enzymes and conserved protein domains to overcome existing resistance mechanisms (Cornell University, 2020).

Other names

Bacterial drug targetsProkaryotic enzymesMicrobial proteinsBacterial protein inhibitors

Antibiotics target bacterial proteins and enzymes to inhibit essential processes: beta-lactams inhibit penicillin-binding proteins (PBPs) to disrupt cell wall synthesis; fluoroquinolones inhibit DNA gyrase and topoisomerase IV to block replication; macrolides and aminoglycosides bind to ribosomal subunits (50S and 30S) to inhibit protein synthesis; and rifamycins inhibit RNA polymerase to block transcription (NIH, 2022; Guide to Pharmacology, 2024).